Former Shire CEO shakes up Galderma as IPO decision looms

Flemming Ørnskov is "doubling down on science" and readying Galderma, formerly owned by Nestle, for competition with the likes of Sanofi.

Photo: Shire/ PR

Flemming Ørnskov led Shire's expansion into rare diseases before the drugmaker's USD 62bn (DKK 399.3bn) sale to Takeda Pharmaceutical Co. in 2019. Now he's plotting a new course for a skincare business that Nestle SA gave up on.

Ørnskov, who took the reins of Switzerland-based Galderma two years ago, said in an interview that he's "doubling down on science," accelerating research spending and adding dermatologists and medical specialists as the company prepares for a potential initial public offering.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs